Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset - HMS LINCS Database

Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

Filter results: >>>>

Cell	Small Molecule	Small Mol Concentration (uM)	Primary Target	Pathway	Mean Normalized Growth Rate Inhibition Value	Increased Fraction Dead
BT-20	Ceritinib	0.0031623	ALK	RTK	1.0478	-0.00217
BT-20	Ceritinib	0.01	ALK	RTK	1.0693	-0.00162
BT-20	Ceritinib	0.1	ALK	RTK	1.0073	0.00247
BT-20	Ceritinib	0.31623	ALK	RTK	0.9637	0.00976
BT-20	Abemaciclib	0.001	CDK4/6	Cell cycle	0.9370	-0.00149
BT-20	Abemaciclib	0.0031623	CDK4/6	Cell cycle	0.8833	-0.00527
BT-20	Abemaciclib	0.031623	CDK4/6	Cell cycle	0.4936	-0.00426
BT-20	Abemaciclib	0.1	CDK4/6	Cell cycle	0.3565	0.00950
BT-20	Abemaciclib	3.1623	CDK4/6	Cell cycle	0.1622	0.01068
BT-20	Abemaciclib	10.0	CDK4/6	Cell cycle	-0.2160	0.37259
BT-20	Palbociclib	0.001	CDK4/6	Cell cycle	1.0987	-0.00539
BT-20	Palbociclib	0.0031623	CDK4/6	Cell cycle	0.9966	0.00011
BT-20	Palbociclib	0.31623	CDK4/6	Cell cycle	0.2359	0.04751
BT-20	Palbociclib	1.0	CDK4/6	Cell cycle	0.2044	0.04646
BT-20	AZD7762	0.001	CHK1/2	Cell cycle	1.1198	-0.00253
BT-20	AZD7762	0.0031623	CHK1/2	Cell cycle	1.2431	-0.00726
BT-20	AZD7762	0.1	CHK1/2	Cell cycle	1.1714	0.04490
BT-20	AZD7762	0.31623	CHK1/2	Cell cycle	0.9454	0.07692
BT-20	AZD7762	3.1623	CHK1/2	Cell cycle	-0.1525	0.50057
BT-20	AZD7762	10.0	CHK1/2	Cell cycle	-0.5785	0.71162
BT-20	Volasertib	0.01	PLK	Cell cycle	0.0133	0.34529
BT-20	Volasertib	0.031623	PLK	Cell cycle	-0.4356	0.63889
BT-20	Volasertib	0.31623	PLK	Cell cycle	-0.5339	0.71936
BT-20	Neratinib	0.031623	EGFR/HER2	RTK	0.9331	0.02815
BT-20	Neratinib	0.01	EGFR/HER2	RTK	0.9924	0.00434